RESUMO
We present a unique case of an aggressive scapular osteoblastoma that produced ß-hCG as a paraneoplastic manifestation in a 20-year-old woman. Serum ß-hCG was found to be elevated during presurgical workup and consequently delayed surgical resection of the increasingly painful tumor because of suspected pregnancy. The paraneoplastic production of ß-hCG was later proven by positive immunohistochemical stain of ß-hCG in a curettage specimen and normalization of ß-hCG levels after surgical resection of the aggressive osteoblastoma. Production of beta-human chorionic gonadotropin (ß-hCG) has been reported in several carcinomas and sarcomas but, to our knowledge, it has not been reported in osteoblastoma in the English-language literature.
Assuntos
Gonadotropina Coriônica Humana Subunidade beta/sangue , Osteoblastoma/sangue , Osteoblastoma/diagnóstico por imagem , Escápula , Biomarcadores Tumorais/sangue , Meios de Contraste , Diagnóstico Diferencial , Feminino , Humanos , Imuno-Histoquímica , Imageamento por Ressonância Magnética , Tomografia Computadorizada por Raios X , Imagem Corporal Total , Adulto JovemRESUMO
The aim of the present study was to identify biomarkers in osteosarcoma (OS) cell serum by antibody microarray profiling, which may be used for OS diagnosis and therapy. An antibody microarray was used to detect the expression levels of cytokines in serum samples from 20 patients with OS and 20 healthy individuals. Significantly expressed cytokines in OS serum were selected when P<0.05 and fold change >2. An enzyme-linked immunosorbent assay (ELISA) was used to validate the antibody microarray results. Finally, classification accuracy was calculated by cluster analysis. Twenty one cytokines were significantly upregulated in OS cell serum samples compared with control samples. Expression of interleukin-6, monocyte chemoattractant protein-1, tumor growth factor-ß, growth-related oncogene, hepatocyte growth factor, chemokine ligand 16, Endoglin, matrix metalloproteinase-9 and platelet-derived growth factor-AA was validated by ELISAs. OS serum samples and control samples were distinguished by significantly expressed cytokines with an accuracy of 95%. The results demonstrated that expressed cytokines identified by antibody microarray may be used as biomarkers for OS diagnosis and therapy.
Assuntos
Biomarcadores Tumorais/sangue , Neoplasias Ósseas/sangue , Condroblastoma/sangue , Citocinas/sangue , Osteoblastoma/sangue , Adolescente , Adulto , Anticorpos/química , Biomarcadores Tumorais/genética , Neoplasias Ósseas/diagnóstico , Neoplasias Ósseas/genética , Neoplasias Ósseas/patologia , Estudos de Casos e Controles , Condroblastoma/diagnóstico , Condroblastoma/genética , Condroblastoma/patologia , Análise por Conglomerados , Citocinas/genética , Ensaio de Imunoadsorção Enzimática , Feminino , Expressão Gênica , Humanos , Masculino , Osteoblastoma/diagnóstico , Osteoblastoma/genética , Osteoblastoma/patologia , Análise Serial de Proteínas/normas , Sensibilidade e EspecificidadeRESUMO
Sera from 62 patients with osteogenic sarcoma and 12 with malignant giant-cell tumour were tested for the presence of immune complexes by the 125I-Clq binding assay. Elevated serum Clq binding activity was found in 67.7% of the osteogenic sarcoma patients and in 75% of the giant-cell tumour patients. These results were compared with those obtained with five sera from patients with benign bone tumours and 20 sera from normal young donors. In the last two groups, the incidence of elevated Clq-binding activity was 0% and 5%, respectively. In some patients with giant-cell tumours, pre- and post-operative serum samples were studied, showing a decrease in test values after tumour resection. Preliminary sequential studies of individual patients indicate that the 125I-Clq binding assay may be useful for monitoring patients with bone tumours.
